Lung adenocarcinoma
Conditions
Interventions
Gold Standard:Pathological diagnosis
Index test:Western blot experiment
Immunohistochemistry experiment
Sponsors
Xuzhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Oncology research is for adults, so the lower age limit is 18 years old and the upper limit is 80 years old; 2. Patients with an ECOG score of less than 2 points; 3. Pathologically diagnosed with lung adenocarcinoma or healthy people; 4. Patients with lung adenocarcinoma are patients who have not undergone standard treatment; 5. The pathology report of patients with lung adenocarcinoma should have measurable lesions; 6. Expected survival>=3 months; 7. Blood routine, liver and kidney function, and some will also require normal urine protein, coagulation function and heart function; 8. Not during pregnancy and lactation. Signed: Subjects sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Have serious heart and brain diseases or other mental diseases; 2. Severe pulmonary fibrosis, especially drug-induced pulmonary fibrosis; 3. Patients with severe pulmonary dysfunction, pulmonary ventilation disorder, and multiple bullae in the past; 4. During pregnancy and lactation; Prior antineoplastic therapy received; 5. Those who have recently undergone major surgery or radiotherapy; 6. Patients who have recently used corticosteroids (glucocorticoids) or immunosuppressants; 7. In addition to the type of primary tumor studied, other primary tumors should be excluded; 8. Exclude active autoimmune disease; 9. Patients with uncontrollable pleural effusion, ascites, or pericardial effusion are excluded; 10. Exclude interstitial lung disease, uncontrollable hypertension, active infection, and cardiovascular and cerebrovascular diseases of great significance; 11. Grade 2/3 immune-related adverse events (irAEs) were excluded; 12. Exclude the presence of known or suspected inability to comply with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor marker CDC73; | — |
Countries
China
Contacts
Public ContactDong Hao
Xuzhou Central Hospital
Outcome results
None listed